Cancer Treatment Reviews
Volume 31, Issue 7 , Pages 582-586 , November 2005

Radiotherapy plus adjuvant goserelin improves survival in men with poor prognosis prostate cancer: Abstracted from: Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of Phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61:1285–90.

  • Mack Roach III, MD, FACR

      Affiliations

    • Corresponding Author InformationTel.: +1 415 353 7175; fax: +1 415 353 9883.

References 

  1. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285–1290
  2. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–106
  3. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21:3972–3978
  4. Granfors T, Modig H, Damber JE, et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol. 1998;159:2030–2034
  5. Roach M, Lu J, Pilepich MV, et al. Predicting long term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys. 2000;47:617–627
  6. Martinez AA, Demanes DJ, Galalae R, et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys. 2005;62:1322–1331
  7. Fiveash JB, Hanks G, Roach M, et al. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys. 2000;47:335–342
  8. D’Amico AV, Renshaw AA, Cote K, et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol. 2004;22:3726–3732
  9. D’Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125–135
  10. Roach M. Neoadjuvant hormonal therapy in men being treated with radiotherapy for localized prostate cancer. Rev Urol. 2004;6:S24–S31
  11. Laverdiere J, Nabid A, De Bedoya LD, et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol. 2004;171:1137–1140
  12. Pilepich MV, Krall JM, Al-Sarraf M, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 1995;45:616–623
  13. D’Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821–827
  14. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904–1911
  15. Group EBCTC. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451–1467

☆ Sources of funding: National Institute of Health, Bethesda, USA.

☆☆ For correspondence: Miljenko V Pilepich, Department of Radiation Oncology, University of California, Los Angeles, School of Medicine, P.O. Box 2515, Los Angeles, CA 90265, United States. Tel: +310 597 5147; fax: +310 457 3451; e-mail: mpilepich@mednet.ucla.edu.

☆☆☆ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(05)00137-4

doi: 10.1016/j.ctrv.2005.08.002

Cancer Treatment Reviews
Volume 31, Issue 7 , Pages 582-586 , November 2005

Article Tools